PT - JOURNAL ARTICLE AU - Ruian Ke AU - Carolin Zitzmann AU - David D. Ho AU - Ruy M. Ribeiro AU - Alan S. Perelson TI - In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness AID - 10.1101/2021.06.26.21259581 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.26.21259581 4099 - http://medrxiv.org/content/early/2021/06/30/2021.06.26.21259581.short 4100 - http://medrxiv.org/content/early/2021/06/30/2021.06.26.21259581.full AB - The within-host viral kinetics of SARS-CoV-2 infection and how they relate to a person’s infectiousness are not well understood. This limits our ability to quantify the impact of interventions on viral transmission. Here, we develop data-driven viral dynamic models of SARS-CoV-2 infection and estimate key within-host parameters such as the infected cell half-life and the within-host reproductive number. We then develop a model linking VL to infectiousness, showing that a person’s infectiousness increases sub-linearly with VL. We show that the logarithm of the VL in the upper respiratory tract (URT) is a better surrogate of infectiousness than the VL itself. Using data on VL and the predicted infectiousness, we further incorporated data on antigen and reverse transcription polymerase chain reaction (RT-PCR) tests and compared their usefulness in detecting infection and preventing transmission. We found that RT-PCR tests perform better than antigen tests assuming equal testing frequency; however, more frequent antigen testing may perform equally well with RT-PCR tests at a lower cost, but with many more false-negative tests. Overall, our models provide a quantitative framework for inferring the impact of therapeutics and vaccines that lower VL on the infectiousness of individuals and for evaluating rapid testing strategies.Significance Quantifying the kinetics of SARS-CoV-2 infection and individual infectiousness is key to quantitatively understanding SARS-CoV-2 transmission and evaluating intervention strategies. Here we developed data-driven within-host models of SARS-CoV-2 infection and by fitting them to clinical data we estimated key within-host viral dynamic parameters. We also developed a mechanistic model for viral transmission and show that the logarithm of the viral load in the upper respiratory tract serves an appropriate surrogate for a person’s infectiousness. Using data on how viral load changes during infection, we further evaluated the effectiveness of PCR and antigen-based testing strategies for averting transmission and identifying infected individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPortions of this work were done under the auspices of the U.S. Department of Energy through Los Alamos National Laboratory, which is operated by Triad National Security, LLC for the National Nuclear Security Administration of the U.S. Department of Energy (contract No. 89233218CNA000001). The work was supported by the Laboratory Directed Research and Development program of Los Alamos National Laboratory (projects No. 20200743ER, 20200695ER, and 20210730ER), by NIH grants R01-AI028433, R01-OD011095 (ASP), R01-AI15270301 (RK) and R01-AI116868 (RMR), by the National Science Foundation RAPID grant PHY-2031756 (ASP), by the Defense Advanced Research Projects Agency (contract No. HR0011938513) and by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE National Laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. This work was competed at the Aspen Center for Physics, which is supported by National Science Foundation grant PHY-1607611.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Human Subjects Research Review Board, Los Alamos National Laboratory.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript